Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.
Department of Medical Biotechnology, University of Siena, Siena, Italy.
Aging (Albany NY). 2020 Mar 9;12(5):4641-4659. doi: 10.18632/aging.102927.
Parkinson is a common neurodegenerative disorder, characterized by motor and non-motor symptoms, including abnormalities in the gut function, which may appear before the motor sign. To date, there are treatments that can help relieve Parkinson' disease (PD)-associated symptoms, but there is no cure to control the onset and progression of this disorder. Altered components of the gut could represent a key role in gut-brain axis, which is a bidirectional system between the central nervous system and the enteric nervous system. Diet can alter the microbiota composition, affecting gut-brain axis function. Gut microbiome restoration through selected probiotics' administration has been reported. In this study, we investigated the effects of the novel formulation SLAB51 in PD. Our findings indicate that this probiotic formulation can counteract the detrimental effect of 6-OHDA and models of PD. The results suggest that SLAB51 can be a promising candidate for the prevention or as coadjuvant treatment of PD.
帕金森病是一种常见的神经退行性疾病，其特征为运动和非运动症状，包括肠道功能异常，这些异常可能出现在运动症状之前。迄今为止，已有一些治疗方法可以帮助缓解帕金森病（PD）相关症状，但尚无控制该疾病发作和进展的方法。肠道的改变成分可能代表着在肠脑轴中起关键作用，这是中枢神经系统和肠神经系统之间的一个双向系统。饮食可以改变微生物群组成，从而影响肠脑轴功能。通过施用选定的益生菌来恢复肠道微生物组已经有报道。在这项研究中，我们研究了新型配方 SLAB51 在 PD 中的作用。我们的研究结果表明，这种益生菌配方可以对抗 6-OHDA 诱导的和 PD 模型的有害作用。这些结果表明，SLAB51 可能是预防或作为 PD 辅助治疗的有前途的候选物。
